TrialDiabetes, obesity & metabolism2017

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.

Melanie J Davies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.